Ethinylestradiol/desogestrel

Desogestrel/ethinylestradiol
	Ethinylestradiol
	Desogestrel
Combination of
Ethinylestradiol	Estrogen
Desogestrel	Progestogen (Progestin)
Clinical data
Trade names	Marvelon, Desogen, Ortho-cept, others
Other names	EE/DSG, EE-DSG, DSG+EE
AHFS/Drugs.com	Professional Drug Facts
MedlinePlus	a601050
Routes of; administration	By mouth
ATC code	G03AA09 (WHO) ;
Legal status
Legal status	CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	71138-35-7;

Ethinylestradiol/desogestrel (EE/DSG), sold under the brand name Marvelon among others, is a fixed-dose combination of ethinylestradiol (EE), an estrogen, and desogestrel (DSG), a progestin, which is used as a birth control pill to prevent pregnancy in women.^[2]^[3]^[5]^[6] It is taken by mouth.^[3]

It was approved for medical use in the United Kingdom in 1981,^[2] and in the United States in 1992.^[3] In 2022, it was the 161st most commonly prescribed medication in the United States, with more than 3 million prescriptions.^[7]^[8]

References

^ "Product monograph brand safety updates". Health Canada. 7 July 2016. Retrieved 3 April 2024.
^ ^a ^b ^c "Marvelon Tablets - Summary of Product Characteristics (SmPC)". (emc). 11 March 2021. Retrieved 18 June 2021.
^ ^a ^b ^c ^d "Desogen Tablets (desogestrel and ethinyl estradiol tablets USP)". DailyMed. 18 June 2018. Retrieved 18 June 2021.
^ "List of nationally authorised medicinal products" (PDF). European Medicines Agency.
^ Pundir J, Coomarasamy A (21 April 2016). Gynaecology: Evidence-Based Algorithms. Cambridge University Press. pp. 260–. ISBN 978-1-316-30110-4.
^ IARC Working Group on the Evaluation of Carcinogenic Risks to Humans; World Health Organization; International Agency for Research on Cancer (2007). Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy. World Health Organization. pp. 435, 436, 455, 459. ISBN 978-92-832-1291-1.
^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
^ "Desogestrel; Ethinyl Estradiol Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

[1] "Product monograph brand safety updates". Health Canada. 7 July 2016. Retrieved 3 April 2024.

[Marvelon_SmPC-2] "Marvelon Tablets - Summary of Product Characteristics (SmPC)". (emc). 11 March 2021. Retrieved 18 June 2021.

[Desogen_FDA_label-3] "Desogen Tablets (desogestrel and ethinyl estradiol tablets USP)". DailyMed. 18 June 2018. Retrieved 18 June 2021.

[4] "List of nationally authorised medicinal products" (PDF). European Medicines Agency.

[PundirCoomarasamy2016-5] Pundir J, Coomarasamy A (21 April 2016). Gynaecology: Evidence-Based Algorithms. Cambridge University Press. pp. 260–. ISBN 978-1-316-30110-4.

[HumansOrganization2007-6] IARC Working Group on the Evaluation of Carcinogenic Risks to Humans; World Health Organization; International Agency for Research on Cancer (2007). Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy. World Health Organization. pp. 435, 436, 455, 459. ISBN 978-92-832-1291-1.

[7] "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.

[8] "Desogestrel; Ethinyl Estradiol Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

See also

References